Scipher Medicine, a leader in precision immunology, has officially launched ClinicalTrialRank.com, an AI-powered platform designed to predict clinical trial failure with remarkable accuracy. The platform aims to revolutionize drug development by helping biopharmaceutical companies and investors avoid costly investments in therapies likely to fail. Built on over a decade of research and technological advancement, ClinicalTrialRank.com leverages Scipher’s deep understanding of the human interactome—the most comprehensive map of protein-protein interactions in biology. This foundation, supported by more than 100 peer-reviewed publications, enables the creation of sophisticated disease models that inform the platform’s predictive capabilities. Reg Seeto, CEO of Scipher Medicine, emphasized the platform’s transformative potential. “The current drug development model is broken—too many promising candidates fail in clinical trials,” he said. “Our earlier tool, PrismRA, has already proven effective in predicting treatment response and is the only CMS-approved treatment classifier in immunology. With ClinicalTrialRank.com, we’re now extending this success to de-risk both pre-clinical and clinical stages. By combining network medicine, AI, and proprietary data, we can dramatically improve the odds of clinical success and redirect billions in wasted R&D spending toward therapies with real potential.” The platform’s advanced architecture integrates a detailed genotype model, a comprehensive phenotype model, and a nuanced treatment model. These layers are superimposed onto the interactome, allowing the system to analyze complex biological patterns from approved drugs and patient responses. It then ranks therapeutic targets based on two key criteria: their genetic relevance to disease and their ability to restore patients’ molecular profiles to a healthy state. Scipher has validated ClinicalTrialRank.com across approximately 25 disease areas. Internal analysis shows that targets ranked poorly by the platform are terminated before clinical launch nearly 100% of the time. This pattern has already identified around 1,000 clinical trials that could have been avoided—potentially saving billions of dollars in development costs. The platform’s launch marks a major step forward for the biopharma industry, offering a powerful tool to de-risk pipelines, optimize R&D portfolios, and guide smarter investment decisions. It not only improves financial efficiency but also accelerates the delivery of effective treatments to patients. Albert-Laszlo Barabasi, PhD, Scipher’s co-founder and a pioneer in network biology, said, “From the start, our mission has been to ensure patients get the right treatment and eliminate wasteful spending. ClinicalTrialRank.com extends this mission into the earliest phases of drug discovery, ensuring only the most promising candidates advance to clinical testing. This isn’t just about saving money—it’s about getting life-changing therapies to patients faster.” Scipher Medicine combines AI, network biology, and proprietary data through its SPECTRA Rx and Dx platforms. The company holds the industry’s largest rheumatoid arthritis clinico-genomic data asset and biobank, along with electronic medical record data from over 3 million rheumatology patients. For more information, visit www.sciphermedicine.com and explore the predictive power of ClinicalTrialRank.com at www.clinicaltrialrank.com.